Kürzlich veröffentlichte Studienresultate

Bargagli M, Scoglio M, Howles S, Fuster DG. Kidney stone disease: risk factors, pathophysiology and management. Nat Rev Nephrol 2025.
https://doi.org/10.1038/s41581-025-00990-x

Scoglio M, Bargagli M, Rintelen F, Roumet M, Trelle S, Fuster DG. Indapamide or chlorthalidone to reduce urine supersaturation for secondary prevention of kidney stones: protocol for a randomised, double-blind, cross-over trial (INDAPACHLOR). BMJ Open. 2025 Jun 16;15(6):e101594. 
https://doi.org/10.1136/bmjopen-2025-101594

Imenez Silva PH, Nasser Dhayat N, Fuster DG, Seeger H, Ritter A, Ernandez T, Buchkremer F, Roth B, Bonny O, Rubio Aliaga I, Wagner CA. Acid excretion is impaired in calcium oxalate stone formers in the Swiss Kidney Stone Cohort. Nephrol Dial Transplant. 2025 Jun 30;40(7):1433-1435. 
https://doi.org/10.1093/ndt/gfaf038

Christe A, Primetis E, Cereghetti GM, Drakopoulos D, Dhayat NA, Bonny O, Ritter A, Mohebbi N, Faller N, Pellegrini L, Bedino G, Venzin RM, Grosse P, Hüsler C, Koneth I, Bucher C, Del Giorno R, Gabutti L, Mayr M, Odermatt U, Buchkremer F, Ernandez T, Stoermann-Chopard C, Teta D,  L, Trelle S, Roth B, Bargagli M, Fuster DG. Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: A Post-Hoc Analysis of the NOSTONE Trial.  Clin J Am Soc Nephrol. 2025 Mar 10.
https://doi.org/10.2215/CJN.0000000659
Online ahead of print. PMID: 40063114.

Anderegg MA, Schietzel S, Bargagli M, Bally L, Faller N, Moor MB, Cereghetti GM, Roumet M, Trelle S, Fuster DG. Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial. Nat Med. 2025 Jan;31(1):286-293. https://doi.org/10.1038/s41591-024-03330-x
Epub 2025 Jan 2. PMID: 39747681.

Stritt K, Fuster DG, Dhayat NA, Bonny O, Faller N, Christe A, Taha A, Ochs V, Ortlieb N, Roth B.  Risk Factors of Asymptomatic Kidney Stone Passage in Adults with Recurrent Kidney Stones. Clin J Am Soc Nephrol. 2024 Jul 19;19(9):1130-7.
https://doi.org/10.2215/CJN.0000000000000496
Online ahead of print. PMID: 39028573.

Anderegg MA, Olinger EG, Bargagli M, Geraghty R, Pohlmeier L, Nater A, Bruggmann R, Sayer JA, Vogt B, Schaller A, Fuster DG. Prevalence and characteristics of monogenic disease in adult kidney stone formers. Nephrol Dial Transplant. 2024 Aug 30;39(9):1426-1441. 
https://doi.org/10.1093/ndt/gfae074
PMID: 38544324.

Dhayat NA, Mattmann C, Seeger H, Ritter A, Ernandez T, Stoermann-Chopard C Buchkremer F, Segerer S, Roth B, Wuerzner G, Wagner CA, Bonny O, Popp AW, Vogt B, Bargagli M, Fuster DG. The Vitamin D metabolite diagnostic ratio associates with phenotypic traits of idiopathic hypercalciuria. Kidney Int Rep. 2024 Jan 10;9(4):1072-1082. 
https://doi.org/10.1016/j.ekir.2024.01.004
eCollection 2024 Apr. PMID: 38765596.

Fuster DG, Bonny O, Roth B. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. Reply. N Engl J Med. 2023 May 25;388(21):2015-2016.
https://doi.org/10.1056/NEJMc2304100
PMID: 37224213.

Dhayat NA, Bonny O, Roth B, Christe A, Ritter A, Mohebbi N, Faller N, Pellegrini L, Bedino G, Venzin RM, Grosse P, Hüsler C, Koneth I, Bucher C, Del Giorno R, Gabutti L, Mayr M, Odermatt U, Buchkremer F, Ernandez T, Stoermann-Chopard C, Teta D, Vogt B, Roumet M, Tamò L, Cereghetti G, Trelle S, Fuster DG. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. N Engl J Med. 2023 Mar 2;388(9):781-791. 
https://doi.org/10.1056/NEJMoa2209275
PMID: 36856614.

Schietzel S, Bally L, Cereghetti G, Faller N, Matthias B Moor, Vogt B, Rintelen F, Trelle S, Fuster DG. Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ Open. 2022 Mar 14;12(3):e059073. 
https://doi.org/10.1136/bmjopen-2021-059073
PMID: 35288397. 

Dhayat NA, Schneider L, Popp AW, Lüthi D, Mattmann C, Vogt B, Fuster DG. Predictors of Bone Mineral Density in Kidney Stone Formers. Kidney Int Rep. 2021 Dec 15;7(3):558-567. 
https://doi.org/10.1016/j.ekir.2021.12.003
 eCollection 2022 Mar. PMID: 35257068.

Somani B, Emiliani E, Knoll T, Mandrile G, Rumsby G, Acquaviva C, Bhojani N, Saeed Bin Hamri S, Bres-Niewada E, Davis NF, Fuster DG, Garrelfs SF, Gauhar V, Hamamoto S, Juliebø-Jones P, Leporati M, Letavernier E, Takayama T, Tzelves L, Kar Kei Yuen S, Ferraro PM. SMART Stone multidisciplinary team (MDT) and patient care: Recommendations for the adult high-risk kidney stone patient pathway. World J Urol. 2025, in press. 

Li Y, Fuster DG, Dhayat NA, Seeger H, Ritter A, Bonny O, Wuerzner G, Ernandez T, Segerer S, Roth B, Rubio-Aliaga I, Wagner CA. Estimating 24-Hour Urine Phosphate Excretion from Spot Urine. Clin Kidney J. 2025. Epub 2025 April 10. 
https://doi.org/10.1093/ckj/sfaf097

Imenez Silva PH, Nasser Dhayat N, Fuster DG, Seeger H, Ritter A, Ernandez T, Buchkremer F, Roth B, Bonny O, Rubio Aliaga I, Wagner CA. Acid excretion is impaired in calcium oxalate stone formers in the Swiss Kidney Stone Cohort. Nephrol Dial Transplant. 2025 Feb 20:gfaf038. 
https://doi.org/10.1093/ndt/gfaf038
Online ahead of print. PMID: 39979031.

Legay C, Haeusermann T, Pasquier J, Chatelan A, Fuster DG, Dhayat N, Seeger H, Ritter A, Mohebbi N, Ernandez T, Stoermann C, Buchkremer F, Segerer S, Wuerzner G, Ammor N, Roth B, Wagner CA, Bonny O, Bochud M. Differences in the food consumption between kidney stone formers and non-formers in the Swiss Kidney Stone Cohort. J Ren Nutr. 2023 Jul;33(4):555-565. 
https://doi.org/10.1053/j.jrn.2023.04.007
Epub 2023 Apr 27. PMID: 37120128.